Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine for Methamphetamine Abstinence in MOUD Adults
NCT06323837Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- Washington State University
- Modality
- Small Molecules
- Drugs
- mirtazapine
- Conditions
- methamphetamine use disorder (MUD)
01
Overview
Phase 2, randomised, double-blind trial in methamphetamine use disorder (MUD) comparing Mirtazapine + Treatment as Usual with Placebo + Treatment as Usual (2 arms). Primary endpoint: Urinanalysis Verified Increased Days of Methamphetamine Abstinence at 22 weeks. Started Jun 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Mirtazapine + Treatment as Usual
Mirtazapine + Treatment as Usual
Placebo + Treatment as Usual
Placebo + Treatment as Usual
03
Who it enrols
Adults with methamphetamine use disorder currently receiving medication for opioid use disorder (methadone or buprenorphine/naloxone), with a positive MA urinalysis, excluding those with severe psychiatric, hepatic, or renal conditions.
04
Endpoints
Primary
Urinanalysis Verified Increased Days of Methamphetamine Abstinence
Secondary
Actigraphy Verified Improved Sleep Patterns
Beyond the preview
Go deeper on NCT06323837.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323837.